image: 1953. Geneticist Dr. Fayette Stephens displays one of the first family trees from the same family with FSHD that continues to work with researchers today.
Credit: Used by permission, Utah Historical Society
Key points:
- FSHD is a rare inherited muscle disorder.
- Some people with FSHD develop symptoms in their teens while others remain nearly unscathed throughout their lives.
- A study with a nine-generation Utah family, who has worked with researchers since the 1940s, has revealed how a genetic “dimmer switch” can protect people from severe symptoms.
IMPACT: The results may open new avenues for therapies to prevent severe FSHD symptoms, accelerate clinical trials, and help patients plan for the future.
Two siblings inherited the same rare genetic disease—a type of muscular dystrophy that progressively weakens the muscles of the face, shoulders, and limbs. Although they shared the same disease-causing genetic change, their outcomes were strikingly different. The brother began noticing weakness in his early teens and could barely walk by his 50s. The sister remained symptom-free into her late 30s and was only mildly affected throughout her life.
The disease is facioscapulohumeral muscular dystrophy (FSHD). If you have the disease-causing genetic change, you will develop the disease—but it’s been a long-standing mystery why some people are severely affected and others have relatively mild symptoms.
Now, research with a nine-generation family shows that the severity of FSHD is strongly influenced by a DNA modification called methylation, which acts like a “dimmer switch” at the disease-causing genetic change, making symptoms milder. The findings could help predict disease outcomes for patients, accelerate clinical trials, and identify new therapeutic targets for treating or preventing FSHD.
“What’s been unexplained through the years is the variability in symptoms among affected individuals,” says Robert Weiss, PhD, professor of human genetics at University of Utah Health and senior author of the study. “Methylation had been suspected, but nobody had clearly unraveled it. This helps clarify a long-standing question in the field.”
The results are published in Brain.
Disease-causing gene is “turned down” in people with mild symptoms
Scientists had known the cause of FSHD for years: a specific genetic change in a gene called DUX4, which is normally active only during early embryonic development. But in people with FSHD, DUX4 becomes active in adulthood as well, triggering a cascade of toxic processes that damage and weaken muscles.
Researchers suspected that disease severity might be influenced by DNA methylation at DUX4. Methylation of DNA acts like a “dimmer switch,” reducing gene activity or turning it off entirely, which could help explain why some people with the same disease-causing DUX4 mutation remain only mildly affected throughout their lives.
By combining historical clinical records with advanced sequencing of stored DNA samples, the researchers found that higher levels of methylation at DUX4 were associated with milder symptoms.
To find this connection, the team needed two things: comprehensive clinical outcome data, and a detailed picture of DUX4 at the molecular level.
They worked with a unique family with FSHD who could trace their ancestry back for nine generations. The family has collaborated with University of Utah geneticists since the 1940s, with DNA samples dating back to the 1980s. “With DNA collected and preserved from multiple generations as far back as the 1980s, this family is a uniquely valuable resource for studying this condition,” says Russell Butterfield, MD, PhD, professor of pediatrics and neurology at U of U Health and lead author of the study.
The team analyzed methylation at DUX4 within the stored DNA samples. This was no simple task, as the DNA region where DUX4 sits is notoriously difficult to study, filled with long, repetitive sequences that make genetic analysis difficult. “It’s the gnarliest gene out there,” Butterfield says. The team developed a targeted long-read sequencing tool to resolve this long, repetitive DNA region and measure methylation on the scale of a single DNA “letter.” Comparing the sequencing data with clinical records revealed the link between methylation and disease severity.
A second genetic change is linked to protective methylation
The level of methylation at DUX4 may be influenced by a change in a second gene that no one had linked to FSHD until now. They compared each participant’s methylation level at DUX4 with their whole-genome sequence, looking for shared patterns of DNA that are associated with differences in methylation.
People with higher levels of methylation at DUX4, they discovered, were more likely to have a specific DNA change near a little-studied gene called HDGFL3. Although the function of HDGFL3 is not well understood, its structure suggests that it may interact with DNA and help regulate methylation. These findings identify HDGFL3 as a gene that may affect disease severity and a potential target for further study.
Future directions
The researchers say that both HDGFL3 and methylation at DUX4 provide avenues for the development of new treatments for muscular dystrophy.
“The key goal is to identify a therapeutic target,” Butterfield explains. “If we can identify a gene that influences whether symptoms begin in the teens versus the 30s or 40s, we may be able to target that pathway with a therapy to slow progression.”
Potential therapies could increase the activity of HDGFL3 or directly increase methylation at DUX4, helping to suppress activity of the disease-causing gene.
A clinical trial designed to increase methylation at DUX4 is currently underway, Butterfield adds. “We just treated our first gene therapy patient a few weeks ago. It’s remarkable to see how quickly these approaches are moving forward.”
In addition to guiding the development of new therapies, understanding how methylation at DUX4 impacts disease severity could help improve prediction of disease progression, allowing for better long-term planning for people with FSHD. The findings may also help accelerate other clinical trials for FSHD by providing a clearer estimate of how symptoms would progress without treatment, making it easier to identify effective therapies.
“We haven’t solved this yet—it’s a challenging problem,” Weiss says. “We’re hopeful that this work will lead to better outcomes for people living with these rare diseases.”
###
The research is published in Brain as "D4Z4 methylation and genetic modifiers influence severity in a facioscapulohumeral muscular dystrophy kindred."
The work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (P50HD060848), Ionis Pharmaceuticals, and the FSHD Society. Content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Journal
Brain
Method of Research
Observational study
Subject of Research
People
Article Title
D4Z4 methylation and genetic modifiers influence severity in a facioscapulohumeral muscular dystrophy kindred.
Article Publication Date
17-Nov-2026
COI Statement
R.J.B. has received funding via contracts for research from Ionis Pharmaceuticals. He serves on scientific advisory boards for Sarepta Therapeutics, Biogen, Novartis, Precision Bio, Solid Bio, and Scholar Rock. K.M.F. has received clinical trial support in the past from Sarepta Therapeutics; currently receives support for the performance of clinical trials from Avidity Therapeutics, Solid Biosciences, and Dyne Therapeutics; and has received compensation for advisory board activities from Avidity, Dyne, Solid Bio, and Armatus. The remaining authors report no competing interests.